



NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR PUBLICATION IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

PRESS RELEASE July 29, 2015

Exercise of the over-allotment option in the IPO of Capio and end of stabilisation period

The Joint Global Coordinators, J.P. Morgan and SEB, have today notified Capio AB (publ) ("Capio") and Ygeia Equity AB¹ ("Ygeia") that the over-allotment option has been exercised in full in respect of 4,812,261 shares in Capio and that the stabilisation period has ended.

In connection with the initial public offering of Capio, Ygeia granted the banks an over-allotment option of up to 4,812,261 shares to be used to cover potential over-allotments of shares. During the stabilisation period, which commenced on June 30, 2015 and ended today, stabilisation has been carried out by SEB as stabilisation manager at the prices specified below. The banks have exercised the over-allotment option in full in respect of 4,812,261 shares.

Following the exercise of the over-allotment option, and taking into consideration the sale of 1,197,176 shares to certain members of Capio's group management and board of directors on July 24, 2015, Ygeia will hold 84,608,473 shares in Capio, corresponding to approximately 59.9 percent of the total number of shares in Capio.

Stabilisation prices per day

June 30, 2015	SEK 48.50
July 1, 2015	SEK 48.50
July 3, 2015	SEK 48.50
July 6, 2015	SEK 48.50

For information, please contact:

Thomas Berglund, President and CEO of Capio
Phone: +46 73 388 8600
Email: thomas.berglund@capio.com

Henrik Brehmer, SVP Corporate Communications and Public Affairs
Phone: +46 76 111 3414
Email: henrik.brehmer@capio.com

About Capio

Capio is a leading, pan-European healthcare provider offering a broad range of high quality medical, surgical and psychiatric healthcare services in four countries through its hospitals, specialist clinics and primary care units. In 2014, Capio's 12,357 employees provided healthcare services during 4.6 million patient visits across the Group's facilities in Sweden, Norway, France and Germany, generating net sales of MSEK 13,200². Capio operates across three geographic segments: Nordic 54 percent of Group net sales, France 37 percent of Group net sales and Germany 9 percent of Group net sales. For more information about Capio, please see www.capio.com.

¹ Ygeia Equity AB is owned by Nordic Capital Fund VI, the Apax Europe VI fund (advised by Apax Partners LLP) and the Apax France VII fund (managed by Apax Partners S.A)

² Pro forma net sales after adjustments MSEK 12,960

Disclaimer

This announcement is not an offer to sell or a solicitation of any offer to buy any securities issued by Capio AB (publ) (the "Company") in any jurisdiction where such offer or sale would be unlawful.

In any EEA Member State, other than Sweden, that has implemented Directive 2003/71/EC as amended (together with any applicable implementing measures in any member State, the "Prospectus Directive"), this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive.

This announcement and the information contained herein are not for distribution in or into the United States of America. This announcement does not constitute an offer to sell, or a solicitation of an offer to purchase or subscribe for, any securities in the United States. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States.

In the United Kingdom, this announcement and any other material in relation to the shares described herein (the "Shares") are being distributed only to, and are directed only at, persons who are "qualified investors" (as defined in the Prospectus Directive) who are (i) persons having professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order, or (iii) persons to whom it would otherwise be lawful to distribute them, all such persons together being referred to as "Relevant Persons". The Shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such Shares will be engaged in only with, Relevant Persons. This announcement should not be distributed, published or reproduced (in whole or in part) or disclosed by any recipients to any other person in the United Kingdom. Any person in the United Kingdom that is not a Relevant Person should not act or rely on this announcement or its contents. The Shares are not being offered to the public in the United Kingdom.

Forward-Looking Statements

Matters discussed in this communication may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe," "expect," "anticipate," "intend," "may," "plan," "estimate," "will," "should," "could," "aim" or "might," or, in each case, their negative, or similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this presentation are free from errors nor does it accept any responsibility for the future accuracy of the opinions

expressed in this presentation or any obligation to update or revise the statements in this presentation to reflect subsequent events. Undue reliance should not be placed on the forward-looking statements in this communication. The information, opinions and forward-looking statements contained in this communication speak only as at its date, and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm, or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this communication.